Literature DB >> 31405855

4-Amino-2-Sulfanylbenzoic Acid as a Potent Subclass B3 Metallo-β-Lactamase-Specific Inhibitor Applicable for Distinguishing Metallo-β-Lactamase Subclasses.

Jun-Ichi Wachino1, Reo Kanechi2, Erina Nishino2, Marie Mochizuki2, Wanchun Jin2, Kouji Kimura2, Hiromasa Kurosaki3, Yoshichika Arakawa2.   

Abstract

The number of cases of infection with carbapenem-resistant Enterobacteriaceae (CRE) has been increasing and has become a major clinical and public health concern. Production of metallo-β-lactamases (MBLs) is one of the principal carbapenem resistance mechanisms in CRE. Therefore, developing MBL inhibitors is a promising strategy to overcome the problems of carbapenem resistance conferred by MBLs. To date, the development and evaluation of MBL inhibitors have focused on subclass B1 MBLs but not on B3 MBLs. In the present study, we searched for B3 MBL (specifically, SMB-1) inhibitors and found thiosalicylic acid (TSA) to be a potent inhibitor of B3 SMB-1 MBL (50% inhibitory concentration [IC50], 0.95 μM). TSA inhibited the purified SMB-1 to a considerable degree but was not active against Escherichia coli cells producing SMB-1, as the meropenem (MEM) MIC for the SMB-1 producer was only slightly reduced with TSA. We then introduced a primary amine to TSA and synthesized 4-amino-2-sulfanylbenzoic acid (ASB), which substantially reduced the MEM MICs for SMB-1 producers. X-ray crystallographic analyses revealed that ASB binds to the two zinc ions, Ser221, and Thr223 at the active site of SMB-1. These are ubiquitously conserved residues across clinically relevant B3 MBLs. ASB also significantly inhibited other B3 MBLs, including AIM-1, LMB-1, and L1. Therefore, the characterization of ASB provides a starting point for the development of optimum B3 MBL inhibitors.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  SMB-1; metallo-beta-lactamase inhibitor

Mesh:

Substances:

Year:  2019        PMID: 31405855      PMCID: PMC6761541          DOI: 10.1128/AAC.01197-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Molecular replacement with MOLREP.

Authors:  Alexei Vagin; Alexei Teplyakov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

2.  Structural Insights into Recognition of Hydrolyzed Carbapenems and Inhibitors by Subclass B3 Metallo-β-Lactamase SMB-1.

Authors:  Jun-Ichi Wachino; Yoshihiro Yamaguchi; Shigetarou Mori; Wanchun Jin; Kouji Kimura; Hiromasa Kurosaki; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

3.  Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing beta-lactamases in Chryseobacterium meningosepticum.

Authors:  S Bellais; D Aubert; T Naas; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  Predictive compound accumulation rules yield a broad-spectrum antibiotic.

Authors:  Michelle F Richter; Bryon S Drown; Andrew P Riley; Alfredo Garcia; Tomohiro Shirai; Riley L Svec; Paul J Hergenrother
Journal:  Nature       Date:  2017-05-10       Impact factor: 49.962

5.  Thiomandelic acid, a broad spectrum inhibitor of zinc beta-lactamases: kinetic and spectroscopic studies.

Authors:  C Mollard; C Moali; C Papamicael; C Damblon; S Vessilier; G Amicosante; C J Schofield; M Galleni; J M Frere; G C Roberts
Journal:  J Biol Chem       Date:  2001-09-19       Impact factor: 5.157

6.  Metallo-beta-lactamase producers in environmental microbiota: new molecular class B enzyme in Janthinobacterium lividum.

Authors:  G M Rossolini; M A Condemi; F Pantanella; J D Docquier; G Amicosante; M C Thaller
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 7.  The rapid spread of carbapenem-resistant Enterobacteriaceae.

Authors:  Robert F Potter; Alaric W D'Souza; Gautam Dantas
Journal:  Drug Resist Updat       Date:  2016-09-19       Impact factor: 18.500

8.  Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound.

Authors:  Yohei Doi; Brian A Potoski; Jennifer M Adams-Haduch; Hanna E Sidjabat; Anthony W Pasculle; David L Paterson
Journal:  J Clin Microbiol       Date:  2008-10-15       Impact factor: 5.948

9.  Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance.

Authors:  E Osano; Y Arakawa; R Wacharotayankun; M Ohta; T Horii; H Ito; F Yoshimura; N Kato
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

10.  Structural Basis of Metallo-β-Lactamase Inhibition by Captopril Stereoisomers.

Authors:  Jürgen Brem; Sander S van Berkel; David Zollman; Sook Y Lee; Opher Gileadi; Peter J McHugh; Timothy R Walsh; Michael A McDonough; Christopher J Schofield
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

View more
  3 in total

1.  Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants.

Authors:  Zishuo Cheng; Christopher R Bethel; Pei W Thomas; Ben A Shurina; John-Paul Alao; Caitlyn A Thomas; Kundi Yang; Steven H Marshall; Huan Zhang; Aidan M Sturgill; Andrea N Kravats; Richard C Page; Walter Fast; Robert A Bonomo; Michael W Crowder
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Practical Agar-Based Disk Diffusion Tests Using Sulfamoyl Heteroarylcarboxylic Acids for Identification of Subclass B1 Metallo-β-Lactamase-Producing Enterobacterales.

Authors:  Chihiro Norizuki; Jun-Ichi Wachino; Wanchun Jin; Kouji Kimura; Kumiko Kawamura; Noriyuki Nagano; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2021-07-14       Impact factor: 5.948

3.  Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance.

Authors:  Jun-Ichi Wachino; Wanchun Jin; Kouji Kimura; Hiromasa Kurosaki; Ayato Sato; Yoshichika Arakawa
Journal:  mBio       Date:  2020-03-17       Impact factor: 7.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.